Figure 4 shows that elevated CEA levels and hepatic steatosis are additive features for the development of IHD. Using pairwise comparison of ROC analyses of incident IHD, the AUC of the groups classified according to elevated CEA levels and hepatic steatosis was significantly higher than that of the group classified based on the presence of hepatic steatosis (p < 0.001). The AUC, sensitivity, and specificity of the groups according to elevated CEA with hepatic steatosis were 0.589, 50.0, and 62.0%, respectively (Table 2). The gene discussed is CEACAM5; the disease is fatty liver disease.